In a pharma trade deal between President Trump and British Prime Minister Starmer, the U.K.’s National Health Service will pay 25% more for innovative medicines.
John Murphy III, president and CEO of the Association for Accessible Medicines, unpacks what’s working, what’s not, and what must change for U.S. generic drug production.
